COMPARISONS IMPROVING PERFUSION IN THE FIELD OF INFARCTION, AND METHODS FOR REPAIRING VASCULAR DAMAGE

摘要

1. The use of a pharmaceutical composition in the manufacture of a medicament for the treatment of adverse ventricular remodeling resulting from damage to a heart attack region due to acute myocardial infarction, wherein the pharmaceutical composition comprises (a) a therapeutic amount of a sterile isolated chemotactic hematopoietic stem cell product that includes a non-swelling, isolated population of autologous mononuclear cells enriched with CD34 + cells that complement they contain a subpopulation of at least 0.5 · 10 highly active SDF-1 motile CD34 + / CXCR-4 + cells that have CXCR-4 mediated chemotactic activity and are effective (i) to reduce cell death of cardiomyocytes by improving perfusion and (ii), to reduce apoptosis, thereby preserving existing cardiomyocytes and their functions in the area of myocardial infarction and providing treatment for adverse ventricular remodeling; (b) a stabilizing amount of serum, and (c) a therapeutically effective amount of at least one o a compatible therapeutic agent selected from the group consisting of a diuretic, an antiarrhythmic agent, an antianginal agent, a cytokine, a tyrosine kinase receptor agonist, a vasoactive agent, an anticoagulant, a fibrinolytic agent and a hypercholesterolemic agent that is effective for promoting the function of existing cardiomyocytes to compensate for the loss of function due to death of cardiomyocytes, where the composition is formulated for parenteral administration through a catheter;